Analysis for CRL

📈 Growth & Financial Trajectory

Over the 8 quarters ending Q2 2026, revenues hovered around $1.0B, starting at about $1.01B in Q3 2024 and ending at about $1.004B in Q2 2026, with a mid‑period dip in Q1 2025 and a rebound into mid‑2025 before a sharper pullback in Q4 2025. Net income swung from a positive $68.7M in Q3 2024 to a large quarterly loss of -$276.29M in Q4 2025, then roughly breakeven to a slight loss (-$0.76M) by Q2 2026. The trajectory is thus flat to modestly volatile with no sustained expansion.

💰 Margins & Cash Flow

Gross profit in Q3 2024 was $349.0M on $1.009B revenue, about a 34.6% margin. Operating income remained positive in several quarters (e.g., Q2 2026: $119.9M), but quarterly results show volatility. Net cash flow from operating activities was consistently positive (e.g., Q2 2026: $179.7M; Q4 2024: $159.4M), while investing/financing activities yielded negative cash in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets around $7.53B, liabilities $4.64B, and equity $2.85B at Q2 2026. Current assets $1.53B vs current liabilities $1.13B yields a healthy ~1.36x current ratio. Operating cash flow remains a strength, with modest leverage evidenced by noncurrent liabilities near $3.51B.

⚠️ Key Drivers & Risks

• Drivers: CRO demand from biotech/pharma; ongoing healthcare/R&D investment.
• Risks: Quarterly earnings volatility and potential one-time or FX effects; sensitivity to contract timing and regulatory shifts.